Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure

Kidney International

Volumn 85, Issue 6, 2014, Pages 1404-1411

  Sapir Pichhadze, Ruth ^a,b   Wang, Yao ^b   Famure, Olusegun ^b   Li, Yanhong ^b   Kim, S Joseph ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

adherence; graft failure; pharmacokinetics; tacrolimus

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLOMERULOPATHY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HIGH RISK PATIENT; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; ADOLESCENT; ADULT; BLOOD; CANADA; DRUG EFFECTS; DRUG MONITORING; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ADULT; DRUG MONITORING; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONTARIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84901837464     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.465     Document Type: Article

References (42)

1. Gill JS, Rose C, Pereira BJ et al. The importance of transitions between dialysis and transplantation in the care of end-stage renal disease patients. Kidney Int 2007; 71: 442-447.
2. Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970-974.
3. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450-462.
4. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289-1295.
5. Thiel G, Bock A, Spondlin M et al. Long-term benefits and risks of cyclosporin a (sandimmun)-an analysis at 10 years. Transplant Proc 1994; 26: 2493-2498.
6. Szczech LA, Berlin JA, Aradhye S et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997; 8: 1771-1777.
7. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patientlevel data. Anti-lymphocyte antibody induction therapy study group. Ann Intern Med 1998; 128: 817-826.
8. Webster AC, Playford EG, Higgins G et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166-176.
9. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
10. Guerra G, Ciancio G, Gaynor JJ et al. Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol 2011; 22: 1758-1768.
11. Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Bmj 2005; 331: 810.
12. Scott LJ, Mckeage K, Keam SJ et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247-1297.
13. Howard RJ, Patton PR, Reed AI et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923-1928.
14. El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
15. Sapir-Pichhadze R, Young A, Joseph Kim S.. Living donor age and kidney transplant outcomes: an assessment of risk across the age continuum. Transplant Int 2013; 26: 493-501.
16. Schnitzler MA, Lentine KL, Gheorghian A et al. Renal function following living, standard criteria deceased and expanded criteria deceased donor kidney transplantation: impact on graft failure and death. Transplant Int 2012; 25: 179-191.
17. Weiner DE, Carpenter MA, Levey AS et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the favorit trial. Am J Transplant 2012; 12: 2437-2445.
18. Ojo A, Wolfe RA, Agodoa LY et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the united states renal data system. Transplantation 1998; 66: 1651-1659.
19. Hsiau M, Fernandez HE, Gjertson D et al. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. Transplantation 2011; 92: 918-922.
20. Venkat VL, Nick TG, Wang Y et al. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence. Pediatr Transplant 2008; 12: 67-72.
21. Pollock-Barziv SM, Finkelstein Y, Manlhiot C et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant 2010; 14: 968-975.
22. Dansirikul C, Staatz CE, Duffull SB et al. Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients. J Clin Pharm Ther 2006; 31: 17-25.
23. Stuber ML, Shemesh E, Seacord D et al. Evaluating non-adherence to immunosuppressant medications in pediatric liver transplant recipients. Pediatr Transplant 2008; 12: 284-288.
24. Borra LC, Roodnat JI, Kal JA et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757-2763.
25. Wolfe RA, Strawderman RL. Logical and statistical fallacies in the use of cox regression models. Am J Kidney Dis 1996; 27: 124-129.
26. Kuypers DR, De Jonge H, Naesens M et al. Effects Of Cyp3a5 and Mdr1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenetics And Genomics 2008; 18: 861-868.
27. Kuypers DR, Vanrenterghem Y. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. Clin Ther 2004; 26: 1834-1844.
28. Kuypers DR, Claes K, Evenepoel P et al. The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients. Drug Metab Dispos 2004; 32: 1421-1425.
29. Lampen A, Christians U, Guengerich FP et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome p450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315-1324.
30. Park SI, Felipe CR, Pinheiro-Machado PG et al. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol 2009; 23: 137-145.
31. Takahashi K, Yano I, Fukuhara Y et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet 2007; 22: 441-444.
32. Toda F, Tanabe K, Ito S et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. Transplant Proc 2002; 34: 1733-1735.
33. Van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002; 25: 707-712.
34. Sellares J, De Freitas DG, Mengel M et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
35. Fine RN, Becker Y, De Geest S et al. Nonadherence consensus conference summary report. Am J Transplant 2009; 9: 35-41.
36. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008; 3(SUPPL. 2): S101-S116.
37. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
38. Solez K, Colvin RB, Racusen LC et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('Can'). Am J Transplant 2007; 7: 518-526.
39. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplantat 2008; 8: 753-760.
40. Snappin SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. Am Stat 2005; 59: 301-307.
41. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28: 964-974.
42. Von Elm E, Altman DG, Egger M et al. The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. Ann Int Med 2007; 147: 573-577.